Rigel Pharmaceuticals Inc (RIGL) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Rigel Pharmaceuticals Inc (NASDAQ:RIGL) is held by 169 institutional firms.

• Institutional ownership in Rigel Pharmaceuticals edged up to 83.8% in September 2025, compared to 77.7% in June 2025.
• Institutional share ownership changed by 7.70% QoQ, while the number of institutional owners saw an increase of 83.70% YoY.
• Of these 169 institutional investors, 103 increased their holdings in Rigel Pharmaceuticals, while 51 of them reduced positions, and 15 investors maintained their exposure.
• This class of investors increased its holdings in Rigel Pharmaceuticals to 15.02Mn shares for the 13F-cycle ending September 2025, up by 1.07Mn shares quarter on quarter, and up 3.12Mn shares year over year.
• As of September 30, 2025, BlackRock, Inc. held Rigel Pharmaceuticals's largest shareholding position with over 1.72Mn shares, representing 9.62% of total outstanding shares.
• Among the most significant buyers of Rigel Pharmaceuticals during September 2025 were GOLDMAN SACHS GROUP INC (554.79K), JANE STREET GROUP, LLC (319.76K), D. E. Shaw & Co., Inc. (306.49K), RENAISSANCE TECHNOLOGIES LLC (237.76K), MARSHALL WACE, LLP (232.38K).
• Leading sellers of Rigel Pharmaceuticals stock in September 2025 included MORGAN STANLEY (1.37Mn), ARMISTICE CAPITAL, LLC (876.00K), Soleus Capital Management, L.P. (328.13K), Assenagon Asset Management S.A. (220.68K), JACOBS LEVY EQUITY MANAGEMENT, INC (164.89K).
• The top 10 institutional holders of Rigel Pharmaceuticals for the quarter ending September 2025 included BlackRock, Inc. (1.72Mn), VANGUARD GROUP INC (1.04Mn), GOLDMAN SACHS GROUP INC (737.03K), ARMISTICE CAPITAL, LLC (724.00K), ACADIAN ASSET MANAGEMENT LLC (685.72K), MARSHALL WACE, LLP (601.33K), Capitolis Liquid Global Markets LLC (591.55K), STATE STREET CORP (554.32K), RENAISSANCE TECHNOLOGIES LLC (474.21K), GEODE CAPITAL MANAGEMENT, LLC (423.72K).